Genetic Test Evaluation

understanding how genetic tests impact patient management

ProstateNext (Ambry Genetics)

August 1, 2018

Prostate cancer is a common cancer in men, a subset of which may be aggressive, resulting in metastases and high mortality. Prostate cancer has a heritable component, with an estimated 57% of the variation in risk attributed to genetic factors. Relative risk of hereditary prostate cancer varies among families and in some pedigrees is strong enough to mimic an autosomal dominant trait. Family linkage studies and genome-wide association studies have identified several genes that are associated to varying degrees with hereditary prostate cancer. Some genes are also related to other hereditary cancer syndromes such as hereditary breast and ovarian cancer. Genetic screening for hereditary prostate cancer that would detect those likely to have or develop cancer that would affect survival is needed. Family members of identified individuals would also benefit from such screening. In a recent study that evaluated 16 genes, 11.8% of men with metastatic prostate cancer had a germline variant whereas only 46% of men with localized prostate cancer had a germline variant. This synopsis evaluates ProstateNext, a 14-gene panel for identification and management of hereditary prostate cancer. This synopsis does not evaluate the evidence for germline cancer gene panel testing, in general, or specific gene associations.